| Active substance | Selpercatinib |
| Holder |
Eli Lilly Benelux N.V. |
| Status | Closed |
| Indication | treatment of adults with advanced or metastatic RET-mutant medullary thyroid cancer (MTC) who require systemic treatment following prior treatment |
| Public documents | Approbation |
| Information for the patient | |
| Informed consent | |
| Last update | 11/08/2022 |